IVDR vs IVDD Classification: Key Regulatory Changes Every IVD Manufacturer Should Understand
Wiki Article
IVDR Classification Mistakes to Avoid When Preparing Your IVD Product for CE Marking
Preparing an in vitro diagnostic medical device for the European market involves several interconnected regulatory activities. Manufacturers must define the intended purpose, demonstrate performance, establish quality management controls, prepare technical documentation, and complete the applicable conformity assessment process. However, one issue can influence almost every subsequent activity: incorrect IVDR classification.
A classification mistake can result in selecting an inappropriate conformity assessment route, preparing insufficient technical documentation, or underestimating notified body involvement. These problems may create additional work during regulatory reviews and affect the manufacturer's CE marking plans.
Under Regulation (EU) 2017/746, manufacturers must classify IVD devices according to the seven rules in Annex VIII. I3CGlobal provides IVDR classification information and consulting resources to help manufacturers understand the four risk classes and their regulatory implications.
Mistake 1: Assuming the Product Technology Determines Its Risk Class
One of the most common classification errors is focusing primarily on the technology used by the product. Manufacturers may assume that products using similar assay technologies should automatically receive the same regulatory classification.
However, the IVDR classification system is based primarily on intended purpose and associated individual and public health risks. Two devices using similar analytical methods can have different classifications because they are designed for different diagnostic applications.
How to Avoid This Mistake
Start by defining the intended purpose in precise terms. Identify the target analyte, medical condition, diagnostic application, specimen type, and intended user. Then evaluate the applicable Annex VIII rules rather than selecting a class based on the product's technology or commercial category.
Mistake 2: Using the Previous IVDD Classification Without Reassessment
The transition from IVDD to IVDR introduced a different classification framework. Under the previous directive, products were grouped into Annex II List A, Annex II List B, self-testing devices, and other devices. The IVDR replaced this structure with four risk classes and seven classification rules.
A product that was previously self-declared under IVDD may require notified body assessment under IVDR. Manufacturers should therefore avoid copying their old classification into the new regulatory documentation without a fresh assessment.
Why Reclassification Matters
The new rules cover a wider range of diagnostic applications. Certain infectious disease assays, genetic tests, oncology markers, and other diagnostic products may fall into Class C or D depending on their intended purpose.
Manufacturers should review every product in their portfolio individually and establish the relevant IVDR classification before planning the conformity assessment process.
Mistake 3: Ignoring the Exceptions Within the Classification Rules
Annex VIII contains several exceptions and distinctions that can significantly affect the final class. A manufacturer who reads only the general wording of a rule may overlook important provisions.
For example, most self-testing devices are Class C under Rule 4, but certain specified products are Class B. These include pregnancy and fertility tests, cholesterol tests, and tests for glucose, erythrocytes, leucocytes, or bacteria in urine.
Rule 2 also contains distinctions for blood grouping systems. Many applications are Class C, while specified systems, including ABO and certain Rhesus, Kell, Kidd, and Duffy systems, fall into Class D.
Carefully reviewing the complete wording of each applicable rule is essential. Manufacturers should not base their decision on a simplified summary alone.
Mistake 4: Overlooking Multiple Intended Purposes
An IVD device may have several intended purposes. For example, a diagnostic platform may support multiple assays, each designed for a different disease or clinical application. These uses may fall under different classification rules.
If a manufacturer evaluates only the most common or lowest-risk application, the resulting classification may be incorrect. The applicable implementing provisions require consideration of the relevant intended purposes, with the highest resulting class taking precedence where multiple rules apply.
Creating a Clear Product Claim Inventory
Manufacturers should create an inventory of all diagnostic claims associated with the device. This should include intended applications described in the instructions for use, labels, product specifications, and other manufacturer-controlled materials.
Each claim should be reviewed against the applicable classification rules. Any proposed change to the intended purpose should trigger a review of the existing classification rationale.
Mistake 5: Treating Software and Accessories as Automatically Having the Same Class
Software and accessories can introduce additional classification considerations. Under the IVDR implementing rules, software that drives or influences an IVD device takes the classification of that device. Standalone IVD software is classified independently using the relevant rules.
Accessories are classified in their own right according to their intended purpose. Calibrators take the class of the devices they are intended to calibrate.
Manufacturers should therefore identify every relevant product component and determine whether it has a separate regulatory classification requirement.
Mistake 6: Confusing Class A With an Absence of Regulatory Obligations
Class A is the lowest IVDR risk category, but it does not mean that the product is exempt from regulatory compliance. Manufacturers must still satisfy the applicable requirements of the regulation.
Class A manufacturers are responsible for preparing technical documentation, demonstrating conformity with applicable general safety and performance requirements, maintaining appropriate processes, and issuing an EU declaration of conformity.
For Class A devices supplied sterile, notified body involvement is required for the manufacturing aspects that establish and maintain sterility. This distinction should be reflected in the regulatory strategy.
Mistake 7: Selecting a Conformity Assessment Route Before Confirming Classification
The conformity assessment route depends on the device's risk class and the applicable regulatory provisions. Planning the notified body process before establishing the correct class can result in an unsuitable regulatory strategy.
Class B, C, and D devices generally require notified body involvement, but the scope of technical documentation assessment and other regulatory activities differs. Class D devices have additional requirements involving EU reference laboratories and batch verification where applicable.
Understanding the Differences Between Classes
Class B devices may undergo quality management system assessment and technical documentation review of representative devices. Class C devices require more extensive technical documentation assessment, while Class D devices are subject to the most extensive conformity assessment provisions.
Manufacturers should review the applicable conformity assessment annexes before selecting a regulatory route.
Mistake 8: Preparing an Incomplete Classification Rationale
A classification decision should be supported by documented reasoning. Simply writing Class B or Class C in a product specification does not explain how the manufacturer reached that conclusion.
A proper rationale should identify the intended purpose, applicable classification rules, relevant exceptions, and final decision. It should also explain why higher-risk rules do not apply when this is relevant to the product.
- Document the intended purpose and diagnostic applications.
- Identify the target analytes and relevant medical conditions.
- Evaluate all potentially applicable Annex VIII rules.
- Record the rationale for selecting the final class.
- Assess software, accessories, and calibrators separately where required.
- Maintain consistency across labelling, instructions for use, and technical documentation.
- Reassess classification whenever the intended purpose changes.
Mistake 9: Underestimating Performance Evaluation Requirements
Classification influences the regulatory pathway, but it should also be considered alongside the performance evaluation strategy. Manufacturers must establish appropriate evidence supporting the scientific validity, analytical performance, and clinical performance of their devices.
Higher-risk diagnostic applications may require more extensive evidence and assessment. Manufacturers should identify the performance claims early and ensure that the evidence strategy supports the intended purpose and regulatory requirements.
Technical documentation should clearly explain the methods used to establish device performance and how the resulting evidence supports the manufacturer's claims.
Mistake 10: Ignoring Regulatory Changes and Transition Conditions
IVDR transition arrangements have been amended over time, and manufacturers should not rely on historical deadlines or outdated regulatory summaries. The applicable conditions depend on the relevant device category and the legal provisions in force.
Companies should monitor the current consolidated regulation, official European Commission guidance, and relevant notified body information. They should also consider notified body capacity, quality management readiness, and the time needed to complete technical documentation.
How I3CGlobal Can Help Manufacturers Understand IVDR Requirements
I3CGlobal provides regulatory consulting resources covering IVDR classification, CE marking, technical documentation, and related medical device compliance activities. Its IVDR classification guide explains the four risk classes, seven Annex VIII rules, and the conformity assessment implications associated with different diagnostic products.
Manufacturers can use this information to understand the classification framework and identify issues that may require a more detailed regulatory assessment. Professional regulatory support may be particularly relevant for products with multiple intended purposes, companion diagnostic applications, software functions, or higher-risk classifications.
Building a More Reliable IVDR Classification Strategy
A reliable classification strategy should be integrated into the product development and regulatory planning process. Manufacturers should define the intended purpose early, evaluate classification rules systematically, and maintain a written justification for every device.
The classification should also be reviewed when the manufacturer introduces new diagnostic claims, changes the intended user, modifies the product's application, or expands the product portfolio. Treating classification as an ongoing regulatory responsibility can help prevent inconsistencies between product development and regulatory documentation.
Conclusion
Incorrect IVDR classification can create avoidable regulatory challenges, including inappropriate conformity assessment planning, incomplete technical documentation, and uncertainty about notified body involvement. Manufacturers should pay particular attention to intended purpose, classification exceptions, multiple diagnostic IVDR Classification applications, software, accessories, and performance evaluation requirements.
A structured review of the seven Annex VIII rules and a well-supported classification rationale provide an important foundation for IVDR CE marking. I3CGlobal offers IVDR Classification IVDR classification information and regulatory consulting resources that can help manufacturers understand the requirements and prepare a more organized regulatory strategy. Report this wiki page